Drug Type Small molecule drug |
Synonyms BMS 919373 |
Target |
Mechanism Kv1.5 blockers(Voltage-gated potassium channel subunit Kv1.5 blockers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H20N6O2S |
InChIKeyXGKULQQVQWCASY-UHFFFAOYSA-N |
CAS Registry1272353-82-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atrial Fibrillation | Phase 2 | US | 25 Jul 2014 | |
Atrial Fibrillation | Phase 2 | CA | 25 Jul 2014 | |
Acute Coronary Syndrome | Phase 1 | - | 01 Mar 2014 |
Phase 2 | 158 | (BMS-919373 3/2 mg) | kqvdaggyds(mafpbpodrv) = vowevwyyri vdxravtofj (svuwcgtmnv, hnauucvvjy - gyrczyfwbe) View more | - | 22 May 2019 | ||
(BMS-919373 8/5 mg) | kqvdaggyds(mafpbpodrv) = qzwkcitbwx vdxravtofj (svuwcgtmnv, octgennptm - bussubcbgv) View more |